Applied Therapeutics Reports Biomarker Data from Pilot Trial of AT-007 in SORD Deficiency

by | Oct 25, 2021 | 0 comments

NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) — Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company
developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported
biomarker data from a pilot trial of AT-007 in patients with SORD Deficiency.

See the complete Press Release.

Learn more on this topic

Related Blog Posts

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news